Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Acq. announced Director departure Appointed director CC transcript
|
X4 Pharmaceuticals, Inc (XFOR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/14/2023 |
SC 13G/A
| ORBIMED ADVISORS LLC reports a 8.2% stake in X4 PHARMACEUTICALS, INC. |
02/14/2023 |
SC 13G/A
| Ikarian Capital, LLC reports a 0.3% stake in X4 PHARMACEUTICALS, INC. |
02/14/2023 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Ikarian Capital, LLC reports a 8.1% stake in X4 PHARMACEUTICALS, INC. |
02/14/2022 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 5.8% stake in X4 Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| RA CAPITAL MANAGEMENT, L.P. reports a 3.9% stake in X4 PHARMACEUTICALS, INC. |
02/14/2022 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in X4 Pharmaceuticals, Inc. |
02/14/2022 |
SC 13G/A
| Bain Capital Life Sciences Fund, L.P. has filed a Schedule 13D for X4 Pharmaceuticals, Inc. |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
05/07/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
04/08/2021 |
SC 13G/A
| Ikarian Capital, LLC reports a 11.1% stake in X4 PHARMACEUTICALS, INC. |
03/25/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/12/2021 |
SC 13G/A
| EcoR1 Capital, LLC reports a 3.6% stake in X4 Pharmaceuticals, Inc. |
02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
12/03/2019 |
SC 13G/A
| Flynn James E reports a 7.2% stake in X4 Pharmaceuticals, Inc. |
10/10/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
08/10/2018 |
SC 13G/A
| FMR LLC reports a 5.4% stake in ARSANIS INC |
02/13/2018 |
SC 13G/A
| FMR LLC reports a 10.8% stake in ARSANIS INC |
|
|